Sana Biotechnology Inc vs TE Connectivity plc Ordinary Shares — how do they compare? Sana Biotechnology Inc trades at $2.76 (market cap $812.76M), while TE Connectivity plc Ordinary Shares trades at $214.01 (market cap $62.49B). The key difference: TE Connectivity plc Ordinary Shares is far larger — about 76.9× Sana Biotechnology Inc's market cap, and TE Connectivity plc Ordinary Shares pays a 1.45% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TEL | |
|---|---|---|
Market Cap | $812.76M | $62.49B |
Volume | 4,314,200 | 1,845,947 |
Sector | Health | Technology |
52-Week High | $5.92 | $249.00 |
52-Week Low | $2.68 | $195.84 |
Typical Hold Time | 23 Days | — |
Enterprise Value | $726.01M | $66.88B |
Dividend Yield | — | 1.45% |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.72, down 1.09% today, showing bearish technical signals with negative moving averages but oversold RSI readings. The company reported no revenue in 2025 with substantial losses (-$244.17M net income) and negative cash flow (-$55.33M), though analyst sentiment remains positive with 82% buy ratings. Recent investor conference presentations highlight ongoing clinical development activities.
While analyst consensus is bullish with a $9.50 price target (Defense World, July 30, 2026), SANA faces significant fundamental challenges including negative profitability metrics and cash burn. Investment appeal hinges on clinical pipeline success, with risks including execution challenges and the pre-revenue biotech business model requiring continued financing.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →TE Connectivity designs and manufactures connectivity and sensor solutions. Its products support transportation, energy networks, industrial automation, communications infrastructure, and medical technology.
Read more on TEL →